![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Sevelamer Carbonate](https://www.pharmacompass.com/image/flap/century-sevelamer-carbonate-desktopgif-46840.gif)
![Sevelamer Carbonate](https://www.pharmacompass.com/image/flap/century-sevelamer-carbonate-mobilegif-68686.gif)
Active Filter(s):
Details:
Lupin received approval from the USFDA for its Abbreviated New Drug Application Sevelamer Carbonate for Oral Suspension, which is a generic equivalent of Renvela® for Oral Suspension, 0.8 g and 2.4 g Packets of Genzyme, used to treat increased phosphate levels in the blood.
Lead Product(s): Sevelamer Carbonate
Therapeutic Area: Nephrology Product Name: Sevelamer Carbonate-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 25, 2021
Details:
Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.
Lead Product(s): Sevelamer Carbonate
Therapeutic Area: Nephrology Product Name: Sevelamer Carbonate-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021